Present and future drug treatments for chronic kidney diseases: Evolving targets in renoprotection

Nature Reviews Drug Discovery

Volumn 7, Issue 11, 2008, Pages 936-953

  Perico, Norberto ^a   Benigni, Ariela ^a   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CAPTOPRIL; CHEMOKINE RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C5 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; EPLERENONE; FELODIPINE; GAMMA SECRETASE INHIBITOR; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; LOSARTAN POTASSIUM; PLACEBO; RAMIPRIL; RENIN INHIBITOR; RITUXIMAB; SPIRONOLACTONE; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNINDEXED DRUG; VALSARTAN; VERAPAMIL; VITAMIN D DERIVATIVE;

ANTIHYPERTENSIVE ACTIVITY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETIC NEPHROPATHY; DISEASE COURSE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; FLUID RETENTION; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER TOXICITY; MONOTHERAPY; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY; KIDNEY DISEASES;

EID: 55349133352     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2685     Document Type: Review

References (212)

1. Dirks, J., Remuzzi, G., Horton, S., Schieppati, A. & Rizvi, S. A. H. in Disease Control Priorities in Developing Countries (eds Jamison, D. T. et al.) 695-706 (Oxford University Press and The World Bank, New York, 2006).
2. Gridelli, B. & Remuzzi, G. Strategies for making more organs available for transplantation. N. Engl. J. Med. 343, 404-410 (2000).
3. Collins, A. J. The hemoglobin link to adverse outcomes. Adv. Stud Med. 3, S14-S17 (2003).
4. Hostetter, T. H., Olson, J. L., Rennke, H. G., Venkatachalam, M. A. & Brenner, B. M. Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am. J. Physiol. 241, F85-F93 (1981).
5. Remuzzi, G., Ruggenenti, P. & Perico, N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann. Intern. Med. 136, 604-615 (2002).
6. Cortes, P., Zhao, X., Riser, B. L. & Narins, R. G. Regulation of glomerular volume in normal and partially nephrectomized rats. Am. J. Physiol. 270, F356-F370 (1996).
7. Hostetter, T. H. Progression of renal disease and renal hypertrophy. Annu. Rev. Physiol. 57, 263-278 (1995).
8. Kang, D. H. et al. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J. Am. Soc. Nephrol. 12, 1434-1447 (2001).
9. Brooks, A. R., Lelkes, P. I. & Rubanyi, G. M. Gene expression profiling of vascular endothelial cells exposed to fluid mechanical forces: relevance for focal susceptibility to atherosclerosis. Endothelium 11, 45-57 (2004).
10. Ingram, A. J., Ly, H., Thai, K., Kang, M. & Scholey, J. W. Activation of mesangial cell signaling cascades in response to mechanical strain. Kidney Int. 55, 476-485 (1999).
11. Harris, R. C., Haralson, M. A. & Badr, K. F. Continuous stretch-relaxation in culture alters rat mesangial cell morphology, growth characteristics, and metabolic activity. Lab. Invest. 66 548-554 (1992).
12. Durvasula, R. V. & Shankland, S. J. Podocyte injury and targeting therapy: An update. Curr. Opin. Nephrol. Hypertens. 15, 1-7 (2006).
13. + channel: Potential implications for the control of glomerular filtration. J. Am. Soc. Nephrol. 15, 2981-2987 (2004).
14. Endlich, N. et al. Podocytes respond to mechanical stress in vitro. J. Am. Soc. Nephrol. 12, 413-422 (2001).
15. Durvasula, R. V. et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int. 65, 30-39 (2004).
16. Anderson, S., Meyer, T. W., Rennke, H. G. & Brenner, B. M. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 76, 612-619 (1985).
17. Zoja, C., Benigni, A. & Remuzzi, G. Cellular responses to protein overload: Key event in renal disease progression. Curr. Opin. Nephrol. Hypertens. 13, 31-37 (2004).
18. Denton, K. M., Anderson, W. P. & Sinniah, R. Effects of angiotensin II on regional afferent and efferent arteriole dimensions and the glomerular pole. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R629-R638 (2000).
19. Kagami, S., Border, W. A., Miller, D. E. & Noble, N. A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J. Clin. Invest. 93, 2431-2437 (1994).
20. Vaughan, D. E., Lazos, S. A. & Tong, K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J. Clin. Invest. 95, 995-1001 (1995).
21. Macconi, D. et al. Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. Am. J. Pathol. 168, 1073-1085 (2006).
22. Rudnicki, M. et al. Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies. Kidney Int. 71, 325-335 (2007).
23. Johnson, D. W., Saunders, H. J., Baxter, R. C., Field, M. J. & Pollock, C. A. Paracrine stimulation of human renal fibroblasts by proximal tubule cells. Kidney Int. 54, 747-757 (1998).
24. Schlondorff, D. O. Overview of factors contributing to the pathophysiology of progressive renal disease. Kidney Int. 74 860-866 (2008).
25. Eddy, A. Role of cellular infiltrates in response to proteinuria. Am. J. Kidney Dis. 37, S25-S29 (2001).
26. Ruggenenti, P., Perna, A., Mosconi, L., Pisoni, R. & Remuzzi, G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int. 53 1209-1216 (1998).
27. Iseki, K., Ikemiya, Y., Iseki, C. & Takishita, S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 63, 1468-1474 (2003).
28. Remuzzi, G. & Bertani, T. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 339, 1448-1456 (1998).
29. Giatras, I., Lau, J. & Levey, A. S. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann. Intern. Med. 127, 337-345 (1997).
30. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349, 1857-1863 (1997).
31. Ruggenenti, P., Perna, A., Gherardi, G., Benini, R. & Remuzzi, G. Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am. J. Kidney Dis. 35, 1155-1165 (2000).
32. Ruggenenti, P., Schieppati, A. & Remuzzi, G. Progression, remission, regression of chronic renal diseases. Lancet 357, 1601-1608 (2001).
33. Jafar, T. H. et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann. Intern. Med. 139, 244-252 (2003).
34. Bakris, G. L. Hypertension and nephropathy. Am. J. Med. 115 (Suppl. 8A), 49S-54S (2003).
35. Ruggenenti, P. et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet 365, 939-946 (2005).
36. Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329, 1456-1462 (1993).
37. Ravid, M. et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 128 982-988 (1998).
38. Ruggenenti, P. et al. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 351, 1941-1951 (2004).
39. Parving, H. H. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345, 870-878 (2001).
40. Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
41. Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
42. de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W. & Unger, T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52, 415-472 (2000).
43. Taal, M. W. & Brenner, B. M. Combination ACEI and ARB therapy: additional benefit in renoprotection? Curr. Opin. Nephrol. Hypertens. 11, 377-381 (2002).
44. Campbell, R. et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int. 63, 1094-1103 (2003).
45. Yusuf, S. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008).
46. Staessen, J. A., Li, Y. & Richart, T. Oral renin inhibitors. Lancet 368, 1449-1456 (2006).
47. Rongen, G. A., Lenders, J. W., Smits, P. & Thien, T. Clinical pharmacokinetics and efficacy of renin inhibitors. Clin. Pharmacokinet. 29, 6-14 (1995).
48. Wood, J. M. et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. 308, 698-705 (2003).
49. Pilz, B. et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46, 569-576 (2005).
50. Stanton, A., Jensen, C., Nussberger, J. & O'Brien, E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42, 1137-1143 (2003).
51. Parving, H. H., Persson, F., Lewis, J. B., Lewis, E. J. & Hollenberg, N. K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446 (2008).
52. Delyani, J. A. Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology. Kidney Int. 57, 1408-1411 (2000).
53. Xue, C. & Siragy, H. M. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 46, 584-590 (2005).
54. Del Vecchio, L., Procaccio, M., Vigano, S. & Cusi, D. Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade. Nature Clin. Pract. Nephrol. 3, 42-49 (2007).
55. Remuzzi, G., Cattaneo, D. & Perico, N. The aggravating mechanisms of aldosterone on kidney fibrosis. J. Am. Soc. Nephrol. 19, 1459-1462 (2008).
56. Fujisawa, G. et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int. 66, 1493-1502 (2004).
57. Han, K. H. et al. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int. 70, 111-120 (2006).
58. Rocha, R., Chander, P. N., Khanna, K., Zuckerman, A. & Stier, C. T. Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31, 451-458 (1998).
59. Nagase, M. et al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47, 1084-1093 (2006).
60. Aldigier, J. C., Kanjanbuch, T., Ma, L. J., Brown, N. J. & Fogo, A. B. Regression of existing glomerulosclerosis by inhibition of aldosterone. J. Am. Soc. Nephrol. 16, 3306-3314 (2005).
61. Schjoedt, K. J. et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 68, 2829-2836 (2005).
62. Epstein, M. et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 1, 940-951 (2006).
63. Bianchi, S., Bigazzi, R. & Campese, V. M. Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study. Am. J. Kidney Dis. 46, 45-51 (2005).
64. Bomback, A. S., Kshirsagar, A. V., Amamoo, M. A. & Klemmer, P. J. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review. Am. J. Kidney Dis. 51, 199-211 (2008).
65. Karet, F. E. & Davenport, A. P. Localization of endothelin peptides in human kidney. Kidney Int. 49, 382-387 (1996).
66. Kohan, D. E. Endothelins in the normal and diseased kidney. Am. J. Kidney Dis. 29, 2-26 (1997).
67. Arai, H., Hori, S., Aramori, I., Ohkubo, H. & Nakanishi, S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348, 730-732 (1990).
68. Sakurai, T. et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348, 732-735 (1990).
69. Davenport, A. P. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol. Rev. 54, 219-226 (2002).
70. Verhaar, M. C. et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97, 752-756 (1998).
71. B-like receptors. Biochem. Biophys. Res. Commun. 184, 100-106 (1992).
72. Remuzzi, G., Perico, N. & Benigni, A. New therapeutics that antagonize endothelin: Promises and frustrations. Nature Rev. Drug Discov. 1, 986-1001 (2002).
73. Benigni, A. et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 44, 440-444 (1993).
74. Nabokov, A. et al. Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol. Dial. Transplant. 11, 514-520 (1996).
75. Benigni, A. et al. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int. 54, 353-359 (1998).
76. Benigni, A. et al. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 47 450-456 (1998).
77. Nakamura, T., Ebihara, I., Tomino, Y. & Koide, H. Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int. 47, 481-489 (1995).
78. Berthold, H., Munter, K., Just, A., Kirchheim, H. R. & Ehmke, H. Contribution of endothelin to renal vascular tone and autoregulation in the conscious dog. Am. J. Physiol. 276, F417-F424 (1999).
79. Imai, T. et al. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 19, 753-757 (1992).
80. Goddard, J. et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: A comparison of selective and combined endothelin receptor blockade. Circulation 109, 1186-1193 (2004).
81. Rubin, L. J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896-903 (2002).
82. Pierre-Paul, D. & Gahtan, V. Noncholesterol-lowering effects of statins. Vasc. Endovascular Surg. 37, 301-313 (2003).
83. Li, C. et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am. J. Physiol. Renal Physiol. 286, F46-F57 (2004).
84. Vieira, J. M., Jr et al. Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol. Dial. Transplant. 20, 1582-1591 (2005).
85. Massy, Z. A., Keane, W. F. & Kasiske, B. L. Inhibition of the mevalonate pathway: Benefits beyond cholesterol reduction? Lancet 347, 102-103 (1996).
86. Zoja, C. et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int. 61, 1635-1645 (2002).
87. Douglas, K., O'Malley, P. G. & Jackson, J. L. Meta-analysis: The effect of statins on albuminuria. Ann. Intern. Med. 145, 117-124 (2006).
88. Strippoli, G. F. et al. Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials. BMJ 336, 645-651 (2008).
89. Sandhu, S., Wiebe, N., Fried, L. F. & Tonelli, M. Statins for improving renal outcomes: A meta-analysis. J. Am. Soc. Nephrol. 17, 2006-2016 (2006).
90. Guthrie, R. M. & Martin, D. R. The safety of rosuvastatin: Effects on renal and hepatic function. Expert Opin. Drug Saf. 6, 573-581 (2007).
91. Baigent, C. & Landry, M. Study of Heart and Renal Protection (SHARP). Kidney Int. Suppl. S207-S210 (2003).
92. Locksley, R. M., Killeen, N. & Lenardo, M. J. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104, 487-501 (2001).
93. Khan, S. B. et al. Antibody blockade of TNF-α reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int. 67, 1812-1820 (2005).
94. Meldrum, K. K. et al. TNF-α neutralization ameliorates obstruction-induced renal fibrosis and dysfunction. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R1456-R1464 (2007).
95. Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285 (2006).
96. Huugen, D., Cohen Tervaert, J. W. & Heeringa, P. TNF-α bioactivity-inhibiting therapy in ANCA-associated vasculitis: Clinical and experimental considerations. Clin. J. Am. Soc. Nephrol. 1 1100-1107 (2006).
97. Mann, D. L. et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 109, 1594-1602 (2004).
98. Sean Eardley, K. & Cockwell, P. Macrophages and progressive tubulointerstitial disease. Kidney Int. 68, 437-455 (2005).
99. Kitagawa, K. et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am. J. Pathol. 165, 237-246 (2004).
100. Lloyd, C. M. et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J. Exp. Med. 185, 1371-1380 (1997).
101. Anders, H. J. et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J. Clin. Invest. 109, 251-259 (2002).
102. Vielhauer, V. et al. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int. 66, 2264-2278 (2004).
103. Topham, P. S. et al. Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J. Clin. Invest. 104, 1549-1557 (1999).
104. Cioli, V. et al. A new protein antidenaturant agent, bindarit, reduces secondary phase of adjuvant arthritis in rats. J. Rheumatol. 19, 1735-1742 (1992).
105. Zoja, C. et al. Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int. 53, 726-734 (1998).
106. Guglielmotti, A. & Dionisio, P. A pharmaceutical composition for the treatment of autoimmune diseases. WO9716185 (1997).
107. Walport, M. J. Complement. First of two parts. N. Engl. J. Med. 344, 1058-1066 (2001).
108. Gerard, N. P. & Gerard, C. The chemotactic receptor for human C5a anaphylatoxin. Nature 349, 614-617 (1991).
109. Wang, Y. et al. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl Acad. Sci. USA 93, 8563-8568 (1996).
110. Hillmen, P. et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355, 1233-1243 (2006).
111. Cybulsky, A. V., Quigg, R. J. & Salant, D. J. Experimental membranous nephropathy redux. Am. J. Physiol. Renal Physiol. 289, F660-F671 (2005).
112. Appel, G. et al. Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy (IMN): Preliminary baseline and pharmacokinetic (PK)/pharmacodynamic (PD) data. J. Am. Soc. Nephrol. 13, 668A (2002).
113. Yu, L., Border, W. A., Huang, Y. & Noble, N. A. TGF-β isoforms in renal fibrogenesis. Kidney Int. 64, 844-856 (2003).
114. Massague, J. & Gomis, R. R. The logic of TGFβ signaling. FEBS Lett. 580, 2811-2820 (2006).
115. Shihab, F. S., Bennett, W. M., Yi, H. & Andoh, T. F. Pirfenidone treatment decreases transforming growth factor-β1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am. J. Transplant. 2, 111-119 (2002).
116. Cain, W. C. et al. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int. J. Immunopharmacol. 20, 685-695 (1998).
117. Giri, S. N., Leonard, S., Shi, X., Margolin, S. B. & Vallyathan, V. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J. Environ. Pathol. Toxicol. Oncol. 18, 169-177 (1999).
118. Callahan, J. F. et al. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-β1) type 1 receptor (ALK5). J. Med. Chem. 45, 999-1001 (2002).
119. Petersen, M. et al. Oral administration of GW788388, an inhibitor of TGF-β type I and II receptor kinases, decreases renal fibrosis. Kidney Int. 73, 705-715 (2008).
120. Gellibert, F. et al. Discovery of 4-{4-[3-(pyridin-2-yl)-1H- pyrazol-4-yl] pyridin-2-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide (GW788388): A potent, selective, and orally active transforming growth factor-β type I receptor inhibitor. J. Med. Chem. 49, 2210-2221 (2006).
121. Ziyadeh, F. N. et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl Acad. Sci. USA 97, 8015-8020 (2000).
122. Shimizu, T. et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int. Suppl. 63, S239-S243 (1997).
123. Shimizu, T. et al. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int. 54, 99-109 (1998).
124. Grygielko, E. T. et al. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-β type I receptor kinase in puromycin-induced nephritis. J. Pharmacol. Exp. Ther. 313, 943-951 (2005).
125. Benigni, A. et al. Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J. Am. Soc. Nephrol. 14, 1816-1824 (2003).
126. Cho, M. E., Smith, D. C., Branton, M. H., Penzak, S. R. & Kopp, J. B. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2, 906-913 (2007).
127. Lebovitz, H. E. & Banerji, M. A. Insulin resistance and its treatment by thiazolidinediones. Recent Prog. Horm. Res. 56, 265-294 (2001).
128. Lebovitz, H. E., Kreider, M. & Freed, M. I. Evaluation of liver function in type 2 diabetic patients during clinical trials: Evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 25, 815-821 (2002).
129. Isshiki, K. et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 49, 1022-1032 (2000).
130. Panchapakesan, U., Pollock, C. A. & Chen, X. M. The effect of high glucose and PPAR-γ agonists on PPAR-γ expression and function in HK-2 cells. Am. J. Physiol. Renal Physiol. 287, F528-F534 (2004).
131. Ohga, S. et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation. Am. J. Physiol. Renal Physiol. 292, F1141-F1150 (2007).
132. Miyazaki, Y., Cersosimo, E., Triplitt, C. & DeFronzo, R. A. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int. 72, 1367-1373 (2007).
133. Jin, H. M. & Pan, Y. Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. Kidney Blood Press. Res. 30, 203-211 (2007).
134. Drazen, J. M., Morrissey, S. & Curfman, G. D. Rosiglitazone - continued uncertainty about safety. N. Engl. J. Med. 357, 63-64 (2007).
135. Goligorsky, M. S., Chaimovitz, C., Rapoport, J., Goldstein, J. & Kol, R. Calcium metabolism in uremic nephrocalcinosis: Preventive effect of verapamil. Kidney Int. 27, 774-779 (1985).
136. Schrier, R. W., Shapiro, J. I., Chan, L. & Harris, D. C. Increased nephron oxygen consumption: Potential role in progression of chronic renal disease. Am. J. Kidney Dis. 23, 176-182 (1994).
137. 3 alters the transforming growth factor beta signaling pathway in renal tissue. J. Surg. Res. 100, 171-175 (2001).
138. 3 targeting of NF-κB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int. 72, 193-201 (2007).
139. 3 is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 110 229-238 (2002).
140. Tan, X., Wen, X. & Liu, Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-κB signaling. J. Am. Soc. Nephrol. 19, 1741-1752 (2008).
141. Levin, A. & Li, Y. C. Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease? Kidney Int. 68, 1973-1981 (2005).
142. Mizobuchi, M. et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J. Am. Soc. Nephrol. 18, 1796-1806 (2007).
143. 3 in experimental mesangial proliferative nephritis in rats. Kidney Int. 60, 87-95 (2001).
144. Tan, X., Li, Y. & Liu, Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J. Am. Soc. Nephrol. 17 3382-3393 (2006).
145. Agarwal, R. et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 68, 2823-2828 (2005).
146. Alborzi, P. et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial. Hypertension 52, 249-255 (2008).
147. Abdel Wahab, N. & Mason, R. M. Connective tissue growth factor and renal diseases: Some answers, more questions. Curr. Opin. Nephrol. Hypertens. 13, 53-58 (2004).
148. Burns, W. C. et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: Implications for diabetic renal disease. J. Am. Soc. Nephrol. 17, 2484-2494 (2006).
149. Okada, H. et al. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J. Am. Soc. Nephrol. 16, 133-143 (2005).
150. Yokoi, H. et al. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 15, 1430-1440 (2004).
151. Ostendorf, T. et al. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J. Am. Soc. Nephrol. 12, 909-918 (2001).
152. Wang, S., Wilkes, M. C., Leof, E. B. & Hirschberg, R. Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. FASEB J. 19, 1-11 (2005).
153. Zoja, C. et al. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int. 70, 97-103 (2006).
154. Lassila, M. et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J. Am. Soc. Nephrol. 16, 363-373 (2005).
155. Floege, J., Eitner, F. & Alpers, C. E. A new look at platelet-derived growth factor in renal disease. J. Am. Soc. Nephrol. 19, 12-23 (2008).
156. Kerkela, R. et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Med. 12, 908-916 (2006).
157. Berman, E. et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N. Engl. J. Med. 354, 2006-2013 (2006).
158. Caenepeel, S., Charydczak, G., Sudarsanam, S., Hunter, T. & Manning, G. The mouse kinome: Discovery and comparative genomics of all mouse protein kinases. Proc. Natl Acad. Sci. USA 101, 11707-11712 (2004).
159. Obligado, S. H., Ibraghimov-Beskrovnaya, O., Zuk, A., Meijer, L. & Nelson, P. J. CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney Int. 73, 684-690 (2008).
160. Lee, M. J. et al. Indirubin-3′-monoxime, a derivative of a Chinese anti-leukemia medicine, inhibits Notch1 signaling. Cancer Lett. 265, 215-225 (2008).
161. Niranjan, T. et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nature Med. 14, 290-298 (2008).
162. Pippin, J. W., Qu, Q., Meijer, L. & Shankland, S. J. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclindependent kinase antagonist. J. Clin. Invest. 100, 2512-2520 (1997).
163. Griffin, S. V., Krofft, R. D., Pippin, J. W. & Shankland, S. J. Limitation of podocyte proliferation improves renal function in experimental crescentic glomerulonephritis. Kidney Int. 67, 977-986 (2005).
164. Gherardi, D. et al. Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J. Am. Soc. Nephrol. 15, 1212-1222 (2004).
165. Zoja, C. et al. Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. Arthritis Rheum. 56, 1629-1637 (2007).
166. Benigni, A. et al. Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis Rheum. 56, 1569-1578 (2007).
167. Nelson, P. J. & Shankland, S. J. Therapeutics in renal disease: The road ahead for antiproliferative targets. Nephron Exp. Nephrol. 103 e6-e15 (2006).
168. Artavanis-Tsakonas, S., Rand, M. D. & Lake, R. J. Notch signaling: Cell fate control and signal integration in development. Science 284 770-776 (1999).
169. Wolfe, M. S. Therapeutic strategies for Alzheimer's disease. Nature Rev. Drug Discov. 1, 859-866 (2002).
170. Shearman, M. S. et al. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid β-protein precursor γ-secretase activity. Biochemistry 39, 8698-8704 (2000).
171. van Es, J. H. et al. Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959-963 (2005).
172. Vujovic, S., Henderson, S. R., Flanagan, A. M. & Clements, M. O. Inhibition of γ-secretases alters both proliferation and differentiation of mesenchymal stem cells. Cell Prolif. 40, 185-195 (2007).
173. Reff, M. E. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435-445 (1994).
174. Coiffier, B. et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92, 1927-1932 (1998).
175. Maloney, D. G. Concepts in radiotherapy and immunotherapy: Anti-CD20 mechanisms of action and targets. Semin. Oncol. 32, S19-S26 (2005).
176. Ruggenenti, P., Cravedi, P. & Remuzzi, G. Latest treatment strategies for membranous nephropathy. Expert Opin. Pharmacother. 8, 3159-3171 (2007).
177. Cohen, C. D. et al. CD20-positive infiltrates in human membranous glomerulonephritis. J. Nephrol. 18, 328-333 (2005).
178. Remuzzi, G. et al. Rituximab for idiopathic membranous nephropathy. Lancet 360, 923-924 (2002).
179. Ruggenenti, P. et al. Rituximab for idiopathic membranous nephropathy: Who can benefit? Clin. J. Am. Soc. Nephrol. 1, 738-748 (2006).
180. Fervenza, F. et al. Variation in response to rituximab in the treatment of idiopathic membranous nephropathy (IMN): Preliminary results at 1 year. J. Am. Soc. Nephrol. 14, A570 (2006).
181. Barsoum, R. S. Hepatitis C virus: From entry to renal injury - facts and potentials. Nephrol. Dial. Transplant. 22, 1840-1848 (2007).
182. Roccatello, D. et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol. Dial. Transplant. 19, 3054-3061 (2004).
183. Sfikakis, P. P. et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial. Arthritis Rheum. 52, 501-513 (2005).
184. van Vollenhoven, R. F. et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand. J. Rheumatol. 33, 423-427 (2004).
185. Gottenberg, J. E. et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64, 913-920 (2005).
186. Remuzzi, A. et al. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int. 69, 1124-1130 (2006).
187. Fioretto, P., Steffes, M. W., Sutherland, D. E., Goetz, F. C. & Mauer, M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med. 339, 69-75 (1998).
188. Ruggenenti, P. et al. In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J. Am. Soc. Nephrol. 10, 997-1006 (1999).
189. Fogo, A. B. New capillary growth: A contributor to regression of sclerosis? Curr. Opin. Nephrol. Hypertens. 14, 201-203 (2005).
190. Oliver, J. A., Maarouf, O., Cheema, F. H., Martens, T. P. & Al-Awqati, Q. The renal papilla is a niche for adult kidney stem cells. J. Clin. Invest. 114, 795-804 (2004).
191. Bahlmann, F. H. et al. Stimulation of endothelial progenitor cells: A new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 45, 526-529 (2005).
192. Morigi, M. et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J. Am. Soc. Nephrol. 15, 1794-1804 (2004).
193. Morigi, M. et al. Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 26, 2075-2082 (2008).
194. Fabry, J. Ein beitrag zur kenntnis der purpura hemorrhagica nodularis (purpura papulosa hemorrhagica hebrae). Arch. Derm. Syphilol. 43, 187-200 (1898).
195. Schiffmann, R. et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285, 2743-2749 (2001).
196. Thurberg, B. L. et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 62, 1933-1946 (2002).
197. Eng, C. M. et al. Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement. Genet. Med. 8, 539-548 (2006).
198. Torres, V. E., Harris, P. C. & Pirson, Y. Autosomal dominant polycystic kidney disease. Lancet 369, 1287-1301 (2007).
199. Torres, V. E. & Harris, P. C. Mechanisms of Disease: Autosomal dominant and recessive polycystic kidney diseases. Nature Clin. Pract. Nephrol. 2, 40-55 (2006).
200. Ruggenenti, P. et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 68, 206-216 (2005).
201. Shillingford, J. M. et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl Acad. Sci. USA 103, 5466-5471 (2006).
202. Tao, Y., Kim, J., Schrier, R. W. & Edelstein, C. L. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J. Am. Soc. Nephrol. 16, 46-51 (2005).
203. Walz, G. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): Is there light at the end of the tunnel? Nephrol. Dial. Transplant. 21, 1752-1757 (2006).
204. Nakamura, T., Miller, D., Ruoslahti, E. & Border, W. A. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-β1. Kidney Int. 41, 1213-1221 (1992).
205. Laiho, M., Saksela, O. & Keski-Oja, J. Transforming growth factor-β induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J. Biol. Chem. 262, 17467-17474 (1987).
206. Kalluri, R. & Neilson, E. G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112, 1776-1784 (2003).
207. Maschio, G. et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 334, 939-945 (1996).
208. Soos, T. J., Meijer, L. & Nelson, P. J. CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases. Drug News Perspect. 19, 325-328 (2006).
209. Nelson, P. J., D'Agati, V. D., Gries, J. M., Suarez, J. R. & Gelman, I. H. Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol. J. Antimicrob. Chemother. 51, 921-929 (2003).
210. Milovanceva-Popovska, M. et al. R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury. Kidney Int. 67, 1362-1370 (2005).
211. Lin, C. L. et al. Wnt/β-catenin signaling modulates survival of high glucose-stressed mesangial cells. J. Am. Soc. Nephrol. 17 2812-2820 (2006).
212. Bukanov, N. O., Smith, L. A., Klinger, K. W., Ledbetter, S. R. & Ibraghimov-Beskrovnaya, O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444, 949-952 (2006).